WO2000041472A3 - Bindungspartner für 5-ht5-rezeptoren zur migränebehandlung - Google Patents
Bindungspartner für 5-ht5-rezeptoren zur migränebehandlung Download PDFInfo
- Publication number
- WO2000041472A3 WO2000041472A3 PCT/EP2000/000142 EP0000142W WO0041472A3 WO 2000041472 A3 WO2000041472 A3 WO 2000041472A3 EP 0000142 W EP0000142 W EP 0000142W WO 0041472 A3 WO0041472 A3 WO 0041472A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- binding partners
- migraine
- receptors
- treatment
- methods
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title abstract 2
- 206010027599 migraine Diseases 0.000 title abstract 2
- 108010006590 serotonin 5 receptor Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00901526A EP1144050A2 (de) | 1999-01-11 | 2000-01-11 | Bindungspartner für 5-ht5-rezeptoren zur migränebehandlung |
JP2000593096A JP2002540063A (ja) | 1999-01-11 | 2000-01-11 | 偏頭痛治療のための5−ht5受容体のための結合パートナー |
AU22891/00A AU2289100A (en) | 1999-01-11 | 2000-01-11 | Binding partners for 5-ht5-receptors for the treatment of migraine |
CA2359360A CA2359360C (en) | 1999-01-11 | 2000-01-11 | In vitro screening method for identifying selective binding partners for 5-ht5-receptors |
MXPA01006986A MXPA01006986A (es) | 1999-01-11 | 2000-01-11 | Contrapartes de union de los receptores 5-ht5 para tratamiento de migrana. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19900674A DE19900674A1 (de) | 1999-01-11 | 1999-01-11 | Bindungspartner für 5-HT5-Rezeptoren zur Migränebehandlung |
DE19900674.1 | 1999-01-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000041472A2 WO2000041472A2 (de) | 2000-07-20 |
WO2000041472A3 true WO2000041472A3 (de) | 2001-10-11 |
Family
ID=7893919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/000142 WO2000041472A2 (de) | 1999-01-11 | 2000-01-11 | Bindungspartner für 5-ht5-rezeptoren zur migränebehandlung |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1144050A2 (de) |
JP (1) | JP2002540063A (de) |
CN (1) | CN1321635C (de) |
AU (1) | AU2289100A (de) |
CA (1) | CA2359360C (de) |
DE (1) | DE19900674A1 (de) |
MX (1) | MXPA01006986A (de) |
WO (1) | WO2000041472A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
WO2007022947A2 (de) | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2105192A (en) * | 1981-08-27 | 1983-03-23 | Shaun R Coughlin | Composition for use in treating atherosclerosis |
WO1994001555A1 (fr) * | 1992-07-01 | 1994-01-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptides ayant une activite de recepteur serotoninergique (5ht5a), acides nucleiques codant pour ces polypeptides et utilisations |
WO1994018319A1 (fr) * | 1993-02-09 | 1994-08-18 | Institut National De La Sante Et De La Recherche Medicale | Nouveaux polypeptides ayant une activite de recepteur serotoninergique, acides nucleiques codant pour ces polypeptides et utilisations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360735A (en) * | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
-
1999
- 1999-01-11 DE DE19900674A patent/DE19900674A1/de not_active Withdrawn
-
2000
- 2000-01-11 AU AU22891/00A patent/AU2289100A/en not_active Abandoned
- 2000-01-11 CA CA2359360A patent/CA2359360C/en not_active Expired - Fee Related
- 2000-01-11 EP EP00901526A patent/EP1144050A2/de not_active Ceased
- 2000-01-11 JP JP2000593096A patent/JP2002540063A/ja active Pending
- 2000-01-11 MX MXPA01006986A patent/MXPA01006986A/es not_active IP Right Cessation
- 2000-01-11 WO PCT/EP2000/000142 patent/WO2000041472A2/de active Application Filing
- 2000-01-11 CN CNB008046107A patent/CN1321635C/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2105192A (en) * | 1981-08-27 | 1983-03-23 | Shaun R Coughlin | Composition for use in treating atherosclerosis |
WO1994001555A1 (fr) * | 1992-07-01 | 1994-01-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptides ayant une activite de recepteur serotoninergique (5ht5a), acides nucleiques codant pour ces polypeptides et utilisations |
WO1994018319A1 (fr) * | 1993-02-09 | 1994-08-18 | Institut National De La Sante Et De La Recherche Medicale | Nouveaux polypeptides ayant une activite de recepteur serotoninergique, acides nucleiques codant pour ces polypeptides et utilisations |
Non-Patent Citations (5)
Title |
---|
"Martindale", PHARMACEUTICAL PRESS, LONDON, XP002140026, 1993 * |
CARSON: "the 5ht5a...", GLIA, vol. 17, no. 4, 1996, pages 317 - 326, XP000913723 * |
See also references of EP1144050A2 * |
SHIMRON: "human 5ht5...", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 233, no. 1, 1997, pages 6 - 9, XP000907456 * |
WEISS: "expression of...", METHODS IN MOLECULAR BIOLOGY, vol. 103, 1998, pages 227 - 239, XP002140017 * |
Also Published As
Publication number | Publication date |
---|---|
EP1144050A2 (de) | 2001-10-17 |
MXPA01006986A (es) | 2002-09-18 |
JP2002540063A (ja) | 2002-11-26 |
DE19900674A1 (de) | 2000-07-13 |
CA2359360C (en) | 2012-11-27 |
WO2000041472A2 (de) | 2000-07-20 |
CN1321635C (zh) | 2007-06-20 |
AU2289100A (en) | 2000-08-01 |
CA2359360A1 (en) | 2000-07-20 |
CN1342070A (zh) | 2002-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2497478A3 (de) | Oligosaccarid-Zusammensetzungen und ihre Verwendung bei der Behandlung von Infektionen | |
WO2005016962A3 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004011611A3 (en) | Taci antibodies and uses thereof | |
WO2001098317A3 (en) | Alpha-glycosylceramides for treating bacterial and fungal infections | |
WO2002089738A3 (en) | Proteomimetic compounds and methods | |
WO2003016475A3 (en) | Nucleic acid and amino acid sequences involved in pain | |
EP1777234A3 (de) | Methoden zur Behandlung von Entzündungskrankheiten unter Verwendung von Agentien welche spezifisch an menschliches Angiopoietin-2 binden | |
WO2003057134A8 (en) | Specific binding agents of human angiopoietin-2 | |
WO2003066661A3 (en) | Human dr4 antibodies and uses thereof | |
WO2004113275A3 (en) | Methods and compositions for treating amyloid-related diseases | |
WO2002040702A3 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
WO2004091572A3 (en) | Cochleate compositions directed against expression of proteins | |
WO2007059341A3 (en) | Pyrazolothiazole protein kinase modulators | |
WO2001079164A3 (en) | N-substituted dithiocarbamates for the treatment of biological disorders | |
WO2005089294A3 (en) | Synthesis of indenoisoquinoliniums and methods of use | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
WO2004099388A3 (en) | Cbl-b polypeptides, complexes and related methods | |
WO2002068476A3 (en) | Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders | |
WO2002039122A3 (en) | Methods for the identification and the treatment of cardiovascular disease | |
WO2005000207A3 (en) | Pcdgf receptor antibodies and methods of use thereof | |
IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
DK1196442T3 (da) | VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser | |
WO2004101766A3 (en) | Grp94-based compositions and methods of use thereof | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
WO2000041472A3 (de) | Bindungspartner für 5-ht5-rezeptoren zur migränebehandlung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00804610.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09869814 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2359360 Country of ref document: CA Ref document number: 2359360 Country of ref document: CA Kind code of ref document: A Ref document number: 2000 593096 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/006986 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000901526 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2000901526 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |